Local drug release systems in endometriosis
editorial
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This review discusses progestin delivery via intrauterine or vaginal administration as a strategy to improve endometriosis treatment efficacy and patient compliance by minimizing systemic side effects.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
n recent years, the research involved to clarify the mechanisms of endometriosis development has opened up new innovative treatments. In fact, not only have new drugs been studied but also new routes of administration for hormones have been investigated. The intrauterine and/or vaginal administration of progestins, such as levonorgestrel and danazol, seems to answer to some problems related to the long-term management of endometriosis in terms of efficacy and compliance.
\n
\nThe medical treatment of endometriosis is significantly influenced by poor compliance and several systemic side-effects. In fact, although a wide armory of medical therapies already exists, the choice depends on patient preference after an appropriate discussion of risks, side-effects and costs. Concerning the hormonal treatment of this pelvic pathology, the European Society for Human Reproduction & Embryology guidelines [1] Kennedy S, Bergqvist A, Chapron C, D'Hooghe T, Dunselman G, Greb R, Hummelshoj L, Prentice A, Saridogan E, on behalf of the ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20: 2698–2704
\n[Crossref], [PubMed], [Web of Science ®], , [Google Scholar]
\n for the diagnosis and treatment of endometriosis affirm (level of evidence A) that ‘suppression of ovarian function for 6 months reduces endometriosis associated pain’. The hormonal drugs investigated (combined oral contraceptives, danazol, gestrinone, medroxyprogesterone acetate and gonadotropin-releasing hormone agonists) are equally effective, but their side-effects and cost profiles differ.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (14)
- A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis via openalex
- Capsule summary via openalex
- Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium via openalex
- Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis via openalex
- ESHRE guideline for the diagnosis and treatment of endometriosis via openalex
- Intravaginal danazol significantly reduces chronic pelvic pain in women with endometriosis via openalex
- Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system via openalex
- Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device via openalex
- Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis via openalex
- The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex
- The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis via openalex
- Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device via openalex
- W2119767373 via openalex
- W2123134517 via openalex
Cited by (3)
Source provenance
- europepmc
- last seen: 2026-08-10T06:11:17.106188+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:14:42.556217+00:00
License: CC0
· commercial use OK